China's Simcere Pharmaceutical H1 revenue rises on neuroscience, autoimmune drugs strength

Simcere Pharmaceutical

20/08/2026 16:02

Overview
China pharmaceutical maker's interim revenue grew 27.8% yr/yr for six months ended June 2026
Net income attributable to equity shareholders rose 37.9% yr/yr for the reporting period
Revenue growth driven by neuroscience and autoimmune drug sales

Outlook
Simcere Pharmaceutical plans to repurchase up to RMB 1 bln of shares from Aug. 21, 2026 under its board-approved mandate

Result Drivers
NEUROSCIENCE SALES - Revenue from neuroscience drugs rose 60.9% yr/yr and accounted for 43.9% of total revenue
AUTOIMMUNE SALES - Autoimmune drug revenue increased 37.8% yr/yr, accounting for 26.4% of total revenue
DECLINE IN OTHER FIELDS - Revenue from other fields fell 25.2% yr/yr

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 4.58 bln
 
H1 Net Income Attributable
 
RMB 829 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Simcere Pharmaceutical Group Ltd is HK$17.35, about 42.2% above its August 20 closing price of HK$12.20
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago

Reuters Recommended Reads
Aug 20 - China's CSPC Pharmaceutical H1 revenue rises on finished drug business growth
Aug 20 - China's top drugmaker Hengrui sees profit growth squeezed by bulk-buying programs
Aug 20 - China's 3SBio H1 net profit falls on higher expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)